#elvitegravir

People who switched to such a regimen gained up to 10 pounds in nine months.

However, all integrase inhibitors were associated with similar weight gain.

Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.

The FDA has approved Gilead’s single-tablet antiretroviral regimen Genvoya, the first HIV treatment to include a new version of tenofovir.

A comparison between the single-tablet HIV med Stribild with a new version of the tablet that includes a revised form of tenofovir has...

Medications used to boost the levels of other HIV antiretrovirals are the most likely out of all ARVs to have dangerous interactions with...

An updated version of Viread (tenofovir) offers slightly better viral suppression and improves indicators of kidney and bone health...

Gilead Sciences has applied to the FDA for approval of yet another combination HIV tablet including an updated version of tenofovir.

Gilead Sciences has filed for FDA approval of a new version of the dual-combination HIV antiretroviral Truvada that is less toxic to the...

Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.

People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug...

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ integrase strand transfer inhibitor Vitekta (elvitegravir) for HIV-p...

One of the most important drugs in the HIV arsenal is getting a tune-up.

The pill has the same antiretrovirals as Stribild, but with a new version of tenofovir.

The FDA has approved Gilead Sciences’ integrase strand transfer inhibitor Vitekta (elvitegravir) for treatment-experienced HIV-positive...

The FDA has accepted Gilead Sciences’ resubmitted applications for the approval of cobicistat and elvitegravir to treat HIV.